Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer
Open Access
- 15 February 2011
- journal article
- review article
- Published by Taylor & Francis Ltd in Cell Cycle
- Vol. 10 (4), 619-624
- https://doi.org/10.4161/cc.10.4.14864
Abstract
Inducible nitric oxide synthase (NOS2) is an inflammation responsive enzyme (EC 1.14.13.39) that is induced during acute and chronic inflammation and tissue injury as part of the host defense and wound healing process. NOS2 up-regulation leads to increased nitric oxide (NO) production, the means by which this enzyme can initiate NO-dependent signal transduction, influence the redox state of cells and induce modifications of proteins, lipids, and DNA. Aberrant expression of NOS2 has been observed in many types of human tumors. In breast cancer, increased NOS2 is associated with markers of poor outcome and decreased survival. Growth factor and cytokine signaling, tissue remodeling, NF-kB activation, and hypoxia are candidate mechanisms that induce NOS2 in tumor epithelial and tumor-infiltrating cells. NOS2 induction will trigger the release of variable amounts of NO into the tumor microenvironment and can activate oncogenic pathways, including the Akt, epidermal growth factor receptor and c-Myc signaling pathways, and stimulate tumor microvascularization. Constitutively increased NO levels may also select for mutant p53 cells to overcome the tumor suppressor function of NO-activated wild-type p53. More recent findings suggest that NO induces stem cell-like tumor characteristics in breast cancer. In this review, we will discuss the effects of NO in tumor biology and disease progression with an emphasis on breast cancer, and will examine the mechanisms that link increased NO to a basal-like transcription pattern in human breast tumors and poor disease outcome.Keywords
This publication has 92 references indexed in Scilit:
- A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancerNature Medicine, 2009
- Nitric Oxide Is a Key Component in Inflammation-Accelerated TumorigenesisCancer Research, 2008
- Hyaluronan-CD44 Interaction Activates Stem Cell Marker Nanog, Stat-3-mediated MDR1 Gene Expression, and Ankyrin-regulated Multidrug Efflux in Breast and Ovarian Tumor CellsPublished by Elsevier BV ,2008
- An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumorsNature Genetics, 2008
- Tumour maintenance is mediated by eNOSNature, 2008
- Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathwaysProceedings of the National Academy of Sciences of the United States of America, 2007
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJama-Journal Of The American Medical Association, 2006
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 2003
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001